

The Journal of Vascular Surgery (J Vasc Bras.) is a peer-reviewed quarterly publication of the Brazilian Society of Angiology and Vascular Surgery (Sociedade Brasileira de Angiologia e de Cirurgia Vascular - SBACV). It is directed to vascular surgeons and clinicians and to professionals of related fields, and accepts submissions in Portuguese, English, and Spanish. The mission of the Journal is to select and disseminate high quality scientific contents concerning original research, novel surgical and diagnostic techniques, and clinical observations in the field of vascular surgery, angiology, and endovascular surgery, as well as reviews and case reports.

[I. EDITORIAL POLICY AND PEER REVIEW](#)

[II. CONFLICT OF INTEREST, HUMAN AND ANIMAL RIGHTS, AND INFORMED CONSENT](#)

[III. MANUSCRIPT PREPARATION AND SUBMISSION](#)

[IV. PUBLICATION CHARGES AND CONTACT INFORMATION](#)

[V. COPYRIGHT AND PUBLICATION LICENSE AGREEMENT](#)

I. EDITORIAL POLICY AND PEER REVIEW

J Vasc Bras. follows the recommendations found in the latest version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (ICMJE). The complete document is available at www.icmje.org.

J Vasc Bras. follows the ethical principles found in the Committee on Publication Ethics (COPE) code of conduct (<http://publicationethics.org/resources/code-conduct>) with regard to duplicate publication, plagiarism, fabricated data, addition or removal of authors, ghost or gift authorship, undisclosed conflict of interest, ethical problems in the study, undue appropriation of ideas or data, response to rumors of misconduct via any media.

Manuscripts that are not in accordance with this instructions will be returned to the authors for correction before review by the Editorial Board.

1. **Originality** - Manuscripts submitted for publication should not have been published nor been submitted for evaluation to other journals in part or in whole.
2. **Copyright** - All accepted manuscripts in J Vasc Bras. except when otherwise stated are published as Full Open Access articles and are freely distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All Authors retain copyright for articles published under this license and are required to submit a Copyright and Publication License Agreement, described below. Articles including previously published figures or other material should cite the original source in the corresponding legends and written permission must be obtained from the copyright holder. We recommend that authors keep a copy of the materials submitted to J Vasc Bras., since they will not be returned to authors.
3. **Editorials** - These papers will have a scientific nature. - J Vasc Bras. will not consider editorials which were not invited by the Editor-in-Chief or which have commercial purposes.
4. **Decision-making process** - Manuscript receipt will be acknowledged via an automatic e-mail message generated by the submission system (<http://mc04.manuscriptcentral.com/jvb-scielo>). If the paper is in accordance with this Instructions to Authors and with the editorial policies of the Journal, it will be reviewed by two referees assigned by the Editor-in-Chief. The process will proceed as follows:

Author Submits

Admin Checks and Passes to EIC (Editor-in-Chief)

Editor-in-Chief Invites and/or Assigns Reviewer(s)

Reviewers Score

Editor-In-Chief Makes Final Decision

Authors and reviewers will remain anonymous throughout the review process. Within 60 days, the authors are informed of either acceptance, rejection, or the need for revisions in the article, as requested by the Editorial Board. A decision letter and reviewers' comments will be e-mailed to the authors. Authors will be requested to return a revised version of the manuscript within 1 month and to provide a letter detailing their responses to the reviewers' comments. Revised manuscripts should clearly indicate changes made to the text, using red font preferably. Revised manuscripts will be sent back to reviewers for reassessment. At this time, a decision will be taken for the acceptance, rejection, or the need for additional revisions.

Below, we disclose the Assessment Questionnaire to the general public, so as to ensure total transparency of the editorial process.

- Does the manuscript contain new and significant information to justify publication?
- Does the Abstract (Summary) clearly and accurately describe the content of the article?
- Is the problem significant and concisely stated?
- Are the methods described comprehensively?
- Are the interpretations and conclusions justified by the results?
- Is adequate reference made to other work in the field?
- Is the language acceptable?
- Please rate the priority for publishing this article (1 is the highest priority, 10 is the lowest priority).
- Manuscript Structure: Is the length of the article, number of tables and figures adequate? Too short/ few? Too long/many?
- Please state any conflict(s) of interest that you have in relation to the review of this paper (state "none" if this is not applicable).
- Please rate the article for Interest, Quality, Originality, and Overall, choosing between Excellent, Good, Average, Below Average, or Poor.
- Confirm that the study was approved by an Ethics Committee.
- Recommendation: Accept, Minor Revision, Major Revision, Reject & Resubmit, or Reject.
- Would you be willing to review a revision of this manuscript?

5. **Authorship** - A maximum of eight authors per manuscript is allowed. Studies with more than eight authors should include a statement providing a reason for the inclusion of each author. In cases of collective (corporate) authorship, the group should identify the individuals taking direct responsibility for the manuscript. According to the Uniform Requirements, edited by the International Committee of Medical Journal Editors (ICMJE), "authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3" (original text available at <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>). Inclusion of authors' names whose contributions do not fulfill these criteria is not recommended nor warranted. Also, authors' names will be published in the exact order in which they appear in the title page of the original submission. The order of authors cannot be changed, and authors cannot be added or removed, after acceptance or during the production stage, unless a justification for such change, in writing, signed by all authors, is timely presented to the Editorial Office team. J Vasc Bras. publishes author contributions. A supplementary statement describing the specific contributions of each author to the study should be provided for each manuscript, as described in detail below.

6. **Decision and translation** - Authors will be informed of the acceptance of their articles via a decision letter sent by our submission system. This message is the official acceptance document issued by the Journal; no other documents will be issued with the same purpose. Once accepted, manuscripts will enter the production process (press) of J Vasc Bras. and will be published in a future issue, as decided by the Editor-in-Chief. Changes to the text or to author names will not be allowed at this stage. Manuscripts accepted in Portuguese or Spanish will be translated into English by the journal's production team, and the translation will be subjected to the corresponding author's approval; manuscripts accepted in English will be revised/copyedited by the journal's production team, and the final version will be subjected to the corresponding author's approval. The editorial office of the Journal will not provide information on the exact date of publication or on the issue in which the article will be published, since the contents of each issue are decided exclusively by the Editor-in-Chief.
7. Before publication, content proofs (in MS Word® DOCX file) and layout proofs (PDF file) are sent to the corresponding author for approval. Authors should download Acrobat Reader (<http://get.adobe.com/br/reader/>, download free of charge) to read the PDF file. Proof corrections should be limited to typesetting errors. No substantial changes will be accepted at this stage. Corrected proofs should be returned within 48 hours of receipt via e-mail. Once the production process of the PDF files is completed, the article will be sent to publication ahead of print at SciELO (<http://www.scielo.br/jvb>).

8. SECTION POLICIES

- 8.1. **Original articles:** J Vasc Bras. publishes complete original articles reporting the results of prospective, experimental, or retrospective studies, as well as articles awarded in congresses. These articles will be given priority for publication. They should be composed of: title page (submitted as a separate file), structured abstract (including the following sections: Background, Objectives, Methods, Results and Conclusions, with no more than 250 words) and keywords in English, structured abstract and keywords in Portuguese (if possible), text (Introduction, Methods, Results, Discussion or equivalent), acknowledgements (if applicable), references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Original articles should not exceed 3,000 words (not including title page, abstract, tables, figures, and references) and 40 references.
- 8.2. **Novel diagnostic, surgical, and clinical treatments:** J Vasc Bras. publishes presentation of novel diagnostic, surgical, and clinical treatments, provided there are no clear or disguised commercial purposes or associations with pharmaceutical or medical device companies. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Innovations should not exceed 3,000 words and 30 references.
- 8.3. **Brief communications:** J Vasc Bras. publishes brief communications, i.e., initial or preliminary and partial results of clinical or surgical studies under development, or reports on the application of an innovative technique. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Brief communications should not exceed 1,500 words and 25 references.
- 8.4. **Review articles:** J Vasc Bras. publishes review articles, including meta- analyses and editorial comments. They should be composed of: title page (submitted as a separate file), unstructured abstract (with no more than 150 words) and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text, references, tables (if applicable), figure legends (if applicable), and figures (if applicable). Review articles are allowed to have up to 5,000 words and 100 references.
- 8.5. **Case reports:** J Vasc Bras. publishes well-documented case reports, of great clinical interest. J Vasc Bras. will only accept cases reporting rare entities, pioneer or innovative treatments, or unexpected results. They should be composed of: title page (submitted as a separate file), unstructured abstract (including no more than 150 words)

and keywords in English, unstructured abstract and keywords in Portuguese (if possible), text (Introduction, Case description and Discussion or equivalent), references, figure legends (if applicable), and figures (if applicable). Case reports should not exceed 1,500 words and 25 references.

- 8.6. **Therapeutic challenge:** J Vasc Bras. publishes therapeutic challenges, divided into four parts, as follows: 1) *Introduction*; 2) *Part I - Clinical situation*, describing the case or situation, including images and/or examinations performed, followed by pertinent questions regarding additional diagnostic means and/or therapeutic conducts; 3) *Part II - What was done*, describing the conduct of choice, including procedures (surgical or clinical), additional examinations, progress of follow-up (if applicable), etc.; 4) *Discussion*, including a final paragraph with the conclusions of the study. They should be composed of: title page (submitted as a separate file), abstract and keywords, in both Portuguese and English, if possible, text, references, tables, figure legends (if applicable), and figures (if applicable). Therapeutic challenges should not exceed 1,500 words and 25 references.
- 8.7. **Letters to the Editor:** J Vasc Bras. publishes letters to the Editor concerning editorial subject or published articles. They should be composed of: title, name of the author (submitted separately), identification of the article commented, and references (if applicable). Letters to the Editor should have no more than 350 words.
- 8.8. **Special Issues:** J Vasc Bras. publishes annals of congresses, guidelines, collections of works presented at conferences sponsored by SBACV, and supplements focusing on specific topics may be organized upon request to the Editor-in-Chief.

II. CONFLICT OF INTEREST, HUMAN AND ANIMAL RIGHTS, AND INFORMED CONSENT

1. **Conflicts of interest and Funding information** - J Vasc Bras. publishes Authors funding and conflict of interest disclosure statement. Authors must disclose, by means of a supplementary statement or along with each author's name, any conflicts of interest that might bias, or in any way impact the integrity of, the submitted manuscript. Some examples include publications, public statements related to the subject of the manuscript, participation in an industry advisory committee, or other activities related to industry sources. Authors should use the list below as a criterion for the statement of potential conflicts of interest:
- to participate in clinical and/or experimental trials supported by a commercial entity;
 - to participate in speaking activities related to industry sources;
 - to be a consultant to or director of a commercial entity;
 - to participate in an industry advisory committee receiving money for completion of research;
 - to receive grant money from a commercial entity;
 - to be a shareholder of a commercial entity;
 - to have a family relationship with owners/directors of a commercial entity having an interest in the subject of the manuscript;
 - to produce scientific reports in journals supported by a commercial entity;
 - to have any financial relationship with people and institutions that might affect the integrity of the manuscript (e.g., being an employee, consultant or shareholder of a commercial entity, receiving honoraria, providing expert testimony, holding patent rights or having a patent application pending, receiving grants or other types of financial support).
 - positive or negative impact on cited companies or products/patents involved in the research.

Note: the ICMJE Conflicts of Interest PDF Form must be used as the basis for this statement and must be completed by all authors (http://www.icmje.org/coi_instructions.html).

2. **Ethics committee** - A statement concerning approval of the study by the institutional research ethics committee (or equivalent) should be included with the manuscript. International authors should state that the manuscript is in accordance with the Helsinki Declaration and with local ethical guidelines. Informed consent should be obtained where appropriate, and this should be clearly indicated in the article. The authors should keep copies of informed consent forms and other documents required by the Ethics Committee at the institution in which the work was carried out. Animal experiments should conform with guidelines applicable to the corresponding type of study.

3. **Registration of Clinical Trials** - J Vasc Bras. supports the policy of registration of clinical trials by the World Health Organization (WHO) and the ICMJE, recognizing the importance of such initiatives for registration and public access to information on clinical trials. According to this recommendation, clinical trials should be registered in one of the Clinical Trials Registries recommended by the WHO and the ICMJE. Addresses are available at the ICMJE website (e.g., www.clinicaltrials.gov, www.ISRCTN.org, www.umin.ac.jp/ctr/index.htm e www.trialregister.nl). In Brazil, clinical trials can be registered on www.ensaiosclinicos.gov.br - Brazilian Clinical Trials Registry/Registro Brasileiro de Ensaios Clínicos (ReBEC). To this end, the first requirement is to obtain a registration number for the study, named UTN (Universal Trial Number), at the link http://www.who.int/ictrp/unambiguous_identification/utn/en/ and also import the xml file of the study registered at Plataforma Brasil (<http://aplicacao.saude.gov.br/plataformabrasil/login.jsf>). The clinical trial registration number should appear in a statement below the abstract. All manuscripts resulting from randomized clinical trials should have a clinical trial registration number.

III. MANUSCRIPT PREPARATION AND SUBMISSION

1. MANUSCRIPT PREPARATION

1.1. Presentation

All manuscripts should be typed double-spaced and left aligned, including all sections: title page, text, references, tables, and figure legends. Manuscripts should be typed as a Microsoft Word® document, font Times New Roman, size 12. Do not highlight any parts of the text using underline or bold. All pages should be numbered. A title page, submitted in a separate file, should contain the following items:

- 1) title of the manuscript in Portuguese;
- 2) title of the manuscript in English;
- 3) short title (do not use acronyms), in the same language of the manuscript (maximum of 50 characters including spaces);
- 4) full names of all authors;
- 5) author affiliations (please inform: Institution - ACRONYM, Department, Municipality, State, Country);
- 6) correspondence information (please inform: name of the corresponding author/Full postal address/Zip code – Municipality (State), Telephone, Country/E-mail);
- 7) author information (please inform: author initials followed by main position/occupation (e.g.: “GBPB holds a MSc degree in Surgery from Universidade Federal de São Paulo (USP)”);
- 8) institution where the study was carried out (e.g.: “This study was carried out at...”).

1.2. Authors and Institutions

Full names of the authors and co-authors, their affiliations and details on the corresponding author (name, address, telephone number, fax, and e-mail) should also be informed in the specific fields of the system (metadata) and removed from the manuscript document to assure blind peer review. Names of the institutions in which the work was carried out or to which the authors are affiliated, as well as congresses where the study was presented, should not be mentioned in the text either. Such information can be provided separately and submitted as a supplementary file. In addition, authors should inform the specific contributions of each author to the study, following the model presented below, including initials of the authors involved in each of the tasks listed:

Conception and design:

Analysis and interpretation:

Data collection:

Writing the article:

Critical revision of the article:

Final approval of the article:

Statistical analysis:

Overall responsibility: Obtained funding:

Note: All authors should have read and approved of the final version of the article submitted to J Vasc Bras.

Do not use capital letters to write names (e.g., SMITH) within the text or in the references.

1.3. Abbreviations

Do not use periods after the letters in acronyms or abbreviations (AAA rather than A.A.A.). The spelled-out forms of abbreviations/ acronyms should be given at first mention, followed by the abbreviation/acronym in parenthesis; thereafter, only the abbreviation/acronym should be used. Abbreviations used in tables and figures should be explained in footnotes, even when they have been previously defined in the text. Names of commercial products should be followed by the trademark symbol (®); the following information should also be mentioned: name of manufacturer, city and country where the product was manufactured.

1.4. Abstract

The use of abbreviations and symbols should be avoided in the abstract. References should not be cited in the abstract.

1.5. Keywords

At least three keywords should be listed below the abstract. Keywords should be in accordance with the Medical Subject Headings (<http://www.nlm.nih.gov/mesh/meshhome.html>), elaborated by the National Library of Medicine.

1.6. Tables

Tables (each table typed on a separate sheet) should be cited in the text and numbered using Arabic numbers in the order in which they appear in the text, with an explanatory title and notes if applicable. Tables should be inserted in the main file, following the references. Use only horizontal borders before and after the header rows and at the foot of the table. Do not use vertical borders and do not split cells diagonally. Tables should not duplicate information previously described in the text. In addition, readers should be able to understand data provided in tables without reference to the text. All abbreviations used in tables should be explained in footnotes; if necessary, symbols should be used to include explanations (*, †, ‡, §, ||, ¶, **, ††, ‡‡, §§, etc.).

1.7. Figures

All figures should be cited in the text (always called “Figure,” not “Graph” or “Image”) and numbered using Arabic numbers in the order in which they appear in the text, with an explanatory legend. All legends should be listed on the same page at the end of the article. Color figures are accepted for online publication, but are printed in black and white; therefore, all figures should be intelligible in black and white.

Figures should be submitted as electronic files (only digital images and photographs will be accepted), in separate files, using extensions .jpg, .gif or .tif, with a resolution of 300 dpi or higher to enable good-quality reproduction. Figures should be submitted electronically. If this is not possible, illustrations should be sent via regular mail. Scanned photographs will not be accepted; paper photographs should be submitted via regular mail. Photographs should not allow patient identification. Graphs should be bidimensional.

If the resolution of the figure submitted electronically is not considered adequate for printing, the Journal may contact the authors and request the submission of a high-resolution version. Identify all photographs sent via regular mail with a label on the back of the figure, indicating first author’s name and top of the figure (with an arrow).

Do not send original X-rays, materials produced in heat-sensitive paper, or any other medical records. Instead, submit two sets of good-quality copies of these materials to enable reproduction.

If the article includes a previously published figure, the original source must be cited in the legend and written permission must be obtained from the copyright holder. Permission for reproduction is required whether the copyright holder is a publishing house or an author, except for public domain documents. Photographs should not allow patient identification. The authors should keep a copy of the permission letter(s).

Figures should not duplicate information previously described in the text. In addition, readers should be able to understand data provided in figures without reference to the text. Abbreviations used in figures should be explained in the legend.

1.8. Acknowledgments

In this section, acknowledge the work of people who contributed intellectually to the manuscript, but whose contribution does not qualify for authorship. Also acknowledge any material support received.

1.9. References

All the authors and works cited in the text should be included in the reference list and vice-versa. References should be numbered consecutively in the order in which they appear in the text (not in alphabetical order), identified by superscript numbers (not by numbers in parentheses). References should follow the order in which they appear in the text. Avoid citing too many references. Select the most relevant references, and focus on the most recent works (past 5 years).

If possible and relevant, cite Brazilian and Latin American authors via the following sources: LILACS (www.bireme.com.br), SciELO (www.scielo.br), J Vasc Bras. (www.scielo.br/jvb e www.jvascbras.com.br).

Avoid citations that are not easily available to readers, such as abstracts presented at conferences, thesis or restricted publications. Do not use “personal communications” as references. Papers that have been accepted for publication but not yet published may be cited followed by the expression “in press.” For citation of other works by the authors, select only original journal articles which are related to the topic under discussion (do not include book chapters or review articles). The authors are responsible for the accuracy of the references and should follow the style shown in the examples below.

Journal articles:

1. Harvey J, Dardik H, Impeduglia T, Woo D, Debernardis F. Endovascular management of hepatic artery pseudoaneurysm hemorrhage complicating pancreaticoduodenectomy. *J Vasc Surg.* 2006;43:613-7.
2. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. *Lancet.* 1998;352:1649-55.
3. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. *Ann Intern Med.* 2001;135:858-69.

If there are more than six authors, cite the first three followed by “et al.” Cite all authors if there are six or fewer. Please note that a period should be inserted after the abbreviated name of the journal.

Book chapters:

4. Rutherford RB. Initial patient evaluation: the vascular consultation. In: Rutherford RB, editor. *Vascular surgery.* Philadelphia: WB Saunders; 2000. p. 1-12.

Journal articles on the Internet:

5. Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. *Am J Nurs* [epub]. 2002 Jun [cited 2002 ago 12];102(6):[approx. 3 p.]. <http://www.nursingworld.org/AJN/2002/june/Wawatch.htm>.

Articles published on the Internet:

6. Wantland DJ, Portillo CJ, Holzemer WL, Slaughter R, McGheeEM. The effectiveness of web-based vs. non-web-based interventions: a meta-analysis of behavioral change outcomes. *J Med Internet Res.* 2004;6(4):e40. <http://www.jmir.org/2004/4/e40/>. Accessed: 29/11/2004.

Websites and online material:

7. OncoLink [Internet site]. Philadelphia: University of Pennsylvania; c1994-2006. [updated 2004 set 24; cited 2006 Mar 14]. <http://cancer.med.upenn.edu/>.

Software:

8. Smallwaters Corporation. Analysis of moment structures: AMOS [software]. Version 5.0.1. Chicago: Smallwaters; 2003.

2. SUBMISSION OF THE ARTICLE

All manuscripts should be submitted via the ScholarOne/ SciELO submission system, available at <http://mc04.manuscriptcentral.com/jvb-scielo>. Register your login data (login and password) and follow the steps in order to submit your manuscript. Before including the manuscript on the submission system, the submitting person should be previously registered on the system as an author by creating/associating an ORCID account (Open Researcher and Contributor ID - <https://orcid.org/>). Likewise, all authors should also register for an ORCID id. ORCID ids are persistent identifiers that distinguish one person from another. Using an ORCID id enables researchers to be easily and accurately linked to their activities, research results, publications, and affiliations. If you have any doubts, please contact the editorial office via e-mail jvascbras@organizasecretaria.com.br or at the telephone number +55 (51) 99977.3480.

IV. PUBLICATION CHARGES AND CONTACT INFORMATION

Manuscript submission and evaluation is free of charge.

J Vasc Bras. is an open-access publication, CC-BY Creative Commons.

All correspondence should be addressed to:

Editorial Office

Rua Quintino Bocaiúva, 1482 - Rio Branco

Zip Code 90440-051 - Porto Alegre, RS

Tel.: +55 (51) 99977.3480 (Veridiana Fraga)

E-mail: jvascbras@organizasecretaria.com.br

V. COPYRIGHT AND PUBLICATION LICENSE AGREEMENT

Dear Editor,

We, the undersigned authors, hereby submit the manuscript entitled “title of study”, written by us and presented as an article for the category “manuscript type” to the Editorial Board of the J Vasc Bras. (Jornal Vascular Brasileiro) for your consideration for publication. In accordance with the “Editorial Policy and Instructions for Authors” we also inform that:

- a) The referred study was performed at (*name of institution*).
- b) The protocol was approved by the institution Ethics Committee (*inform institution name and number of protocol*).
- c) Informed consent was obtained for studies that involved humans.
- d) We acknowledge and agree that if accepted for publication the copyright shall be retained by all author of the study, except where otherwise noted, are that the article will be published under a Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- e) We have kept a copy of the submitted manuscript; and
- f) All support, funding and conflict of interest have been fully disclosed by all authors individually using the PDF form mentioned in section “II 1. Conflicts of interest and Funding information”.. The statements must include but are not limited to institutions names and grant proposal numbers, relationships that involve, professional, financial, or direct or indirect beneficiary conflicts of interest, or explicitly declare the inexistence of such associations.

Funding and conflict of interest:

(type here the statement for each author)

To facilitate correspondence exchange, the following author was designated as the correspondence author:

Name of corresponding author

Current affiliation institution

Complete postal address

Telephone number

E-mail address

We presently submit and await manifestation of notification.

Sincerely,

(Date and location, followed by the signatures and respective full names of all authors)